Please login to the form below

Not currently logged in
Email:
Password:

Medius Deal Watch table for April 2015

The top major pharma mergers, acquisitions and collaborations during the month continued pharma's love affair with oncology

This month's deals continue pharma's ongoing love affair with the oncology sector, with at least eight of the deals reported in our top 20 deals of the month in this field.

The prize to the most industrious company this month must go to Celgene as it racked up five deals in the month, with four in just one week! Astra Zeneca (AZ) and Sanofi have also had busy months with three deals apiece; AZ with a focus on looking at combining its lead checkpoint inhibitor with other therapies specifically to target blood cancers. Meanwhile Sanofi is looking to improve its in-house R&D success-rates and reprioritise its portfolio. [Read the month's pharma deal commentary in full.]

Here Medius present a run down of the month's biggest mergers, acquisitions and collaborations from across the sector.

Licensor Acquired / Licensee Acquiror
Deal type
Product/Technology
Headline $m
Mylan/Teva
Corporate acquisition *
Generics company
40,000
Perrigo/Mylan
Corporate acquisition *
Generics / OTC company
32,700
uniQure NV/ Bristol-Myers Squibb
R&D collaboration plus equity investment
Gene therapy platform - CV diseases
2,300
Innate Pharma / AstraZeneca
Licence
IPH2201 an anti NKG2A antibody, a first in class humanised IgG4 antibody
1275
Curadev Pharma /Roche
R&D collaboration
IDO1 and TDO inhibitors (enzymes to mediate cancer-induced immune suppression)
555
Quanticel /Celgene
Corporate acquisition
Drug discovery business using single cell genomic analysis to decode tumours
485
AstraZeneca/Celgene
Exclusive collaboration
MEDI4736 - an investigational checkpoint inhibitor in serious blood cancers
450
Arvinas /Merck & Co
R&D collaboration plus option
PROTAC (proteolysis-targeting chimera) technology that degrades proteins
434
Ridley/Alltech
Corporate acquisition
Animal nutrition business
425
Resverlogix/ Shenzhen Hepalink
Licence and equity investment
RVX 208 a selective BET bromodomain inhibitor [turns disease causing genes off] P3 ready - cardiovascular disease patients
400
Inarcia therapeutics / Investors
Synthetic royalty rights
ICTA650 extended sub-cutaneous delivery of GLP-1 for T2DM
225
Intec Pharma/ Undisclosed Company
R&D collaboration plus option
Accordian Pill ™ (gastro retentive delivery system)
151
UCB/ Dr. Reddy's
Business acquisition
Dermatology, respiratory and paediatric products for South Asia**
128
Schrodinger/ Sanofi
R&D collaboration
Computational drug design for 10 discovery programs
120
4SC AG/Menarini
Licensing and development agreement***
Resminostat (oral HDAC) for hepatocellular carcinoma
102
Ichor Medical Systems/ Janssen Pharmaceuticals
R&D collaboration
DNA based vaccines Chronic Hep B using TriGrid electroporation delivery
85
Agios Pharmaceuticals / Celgene
R&D collaboration and profit share
AG-881 IDH (isocitrate dehydrogenase) mutant inhibitor targets cancer metabolism in blood and solid tumours (AML and glioma)
80
Innocutis Holdings / Cipher Pharmaceuticals
Corporate acquisition
Dermatology company with US, Canada and Mexico rights to Sitavig
49
Mesoblast / Celgene
Minority investment and option to license
stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications
45
Northern Biologics / Celgene
R&D collaboration and option to acquire
therapeutic antibodies in oncology and fibrosis
30

* These transactions are not agreed, as of 7 May 2015, both have been rejected by the target companies

**South Asia (India, Nepal, Sri Lanka and the Maldives) INR 800 Crores

***Asia pacific (Australia,China,Indonesia,Philippines,Republic of Korea,Thailand,Vietnam) €95m 

14th May 2015

14th May 2015

From: Research, Sales

Share

Tags


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Infographics